KR20050003415A - 카르바메이트-치환된 피라졸로피리딘 - Google Patents
카르바메이트-치환된 피라졸로피리딘 Download PDFInfo
- Publication number
- KR20050003415A KR20050003415A KR10-2004-7017877A KR20047017877A KR20050003415A KR 20050003415 A KR20050003415 A KR 20050003415A KR 20047017877 A KR20047017877 A KR 20047017877A KR 20050003415 A KR20050003415 A KR 20050003415A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- mmol
- fluorobenzyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (14)
- 화학식 I의 화합물, 및 그의 염, 이성질체 및 수화물.[화학식 I]식 중에서,R1은 -NR3C(=O)OR4이고,R2는 수소 또는 NH2이고,R3는 수소 또는 (C1-C4)-알킬이고,R4는 (C1-C6)-알킬이다.
- 제1항에 있어서,R1이 -NR3C(=O)OR4이고,R2가 수소 또는 NH2이고,R3가 (C1-C4)-알킬이고,R4가 (C1-C4)-알킬인 화합물, 및 그의 염, 이성질체 및 수화물.
- 제1항에 있어서,R1이 -NR3C(=O)OR4이고,R2가 NH2이고,R3가 메틸 또는 에틸이고,R4가 메틸, 에틸 또는 이소프로필인 화합물, 및 그의 염, 이성질체 및 수화물.
- 제1항에 있어서, 하기 구조식의 메틸 4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리딘-3-일]-5-피리미디닐(메틸)카르바메이트인 화합물, 및 그의 염, 이성질체 및 수화물.
- [A] 화학식 Ia의 화합물을 화학식 II의 화합물과 반응시키거나, 또는 [B] 화학식 III의 화합물을 화학식 IV의 화합물과 반응시키거나, 또는 [C] 화학식 V의 화합물을 화학식 VI의 화합물과 반응시켜 화학식 Ib의 화합물을 수득하는 것을 특징으로 하는, 제1항에서 정의한 바와 같은 화학식 I의 화합물의 제조 방법.[화학식 Ia][화학식 II][화학식 III][화학식 IV][화학식 V][화학식 VI][화학식 Ib]식 중에서,R3및 R4는 제1항에서 정의한 바와 같고,X1은 이탈기이다.
- 제1항에 있어서, 질환을 치료하기 위한 화학식 I의 화합물.
- 하나 이상의 제1항에 따른 화학식 I의 화합물 및 하나 이상의 추가의 부형제를 포함하는 의약.
- 하나 이상의 제1항에 따른 화학식 I의 화합물을 하나 이상의 유기 니트레이트 또는 NO 공여체와 함께 포함하는 의약.
- 하나 이상의 제1항에 따른 화학식 I의 화합물을, 시클릭 구아노신 모노포스페이트 (cGMP)의 분해를 억제하는 하나 이상의 화합물과 함께 포함하는 의약.
- 심혈관 장애 치료용 의약의 제조를 위한, 제1항에 따른 화학식 I의 화합물의 용도.
- 고혈압 치료용 의약의 제조를 위한, 제1항에 따른 화학식 I의 화합물의 용도.
- 혈전색전증 및 허혈 치료용 의약의 제조를 위한, 제1항에 따른 화학식 I의 화합물의 용도.
- 성 기능장애, 특히 발기부전 및 여성 성 기능장애 치료용 의약의 제조를 위한, 제1항에 따른 화학식 I의 화합물의 용도.
- 제10항 내지 제13항 중의 어느 한 항에 있어서, 제1항에 따른 화학식 I의 화합물이 하나 이상의 유기 니트레이트 또는 NO 공여체, 또는 시클릭 구아노신 모노포스페이트 (cGMP)의 분해를 억제하는 하나 이상의 화합물과 함께 사용되는 것인 용도.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10220570A DE10220570A1 (de) | 2002-05-08 | 2002-05-08 | Carbamat-substituierte Pyrazolopyridine |
DE10220570.1 | 2002-05-08 | ||
PCT/EP2003/004304 WO2003095451A1 (de) | 2002-05-08 | 2003-04-25 | Carbamat-substituierte pyrazolopyridine |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050003415A true KR20050003415A (ko) | 2005-01-10 |
KR101011864B1 KR101011864B1 (ko) | 2011-02-01 |
Family
ID=29265155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047017877A KR101011864B1 (ko) | 2002-05-08 | 2003-04-25 | 카르바메이트-치환된 피라졸로피리딘 |
Country Status (39)
Country | Link |
---|---|
US (1) | US7173037B2 (ko) |
EP (1) | EP1506193B1 (ko) |
JP (1) | JP4455321B2 (ko) |
KR (1) | KR101011864B1 (ko) |
CN (1) | CN1330649C (ko) |
AR (1) | AR039789A1 (ko) |
AT (1) | ATE330957T1 (ko) |
AU (1) | AU2003233061B2 (ko) |
BE (1) | BE2014C030I2 (ko) |
BR (1) | BRPI0309855B8 (ko) |
CA (1) | CA2485143C (ko) |
CU (1) | CU23453B7 (ko) |
CY (2) | CY1105579T1 (ko) |
DE (2) | DE10220570A1 (ko) |
DK (1) | DK1506193T3 (ko) |
DO (1) | DOP2003000639A (ko) |
EC (1) | ECSP045414A (ko) |
ES (1) | ES2268363T3 (ko) |
FR (1) | FR14C0032I2 (ko) |
GT (1) | GT200300101A (ko) |
HK (1) | HK1082247A1 (ko) |
HR (1) | HRP20041166B1 (ko) |
IL (1) | IL164958A (ko) |
LU (1) | LU92419I2 (ko) |
MX (1) | MXPA04011003A (ko) |
MY (1) | MY136841A (ko) |
NL (1) | NL300659I2 (ko) |
NO (2) | NO329105B1 (ko) |
NZ (1) | NZ536417A (ko) |
PE (1) | PE20040197A1 (ko) |
PL (1) | PL214985B1 (ko) |
PT (1) | PT1506193E (ko) |
RU (1) | RU2339638C9 (ko) |
SI (1) | SI1506193T1 (ko) |
TW (1) | TWI282792B (ko) |
UA (1) | UA78314C2 (ko) |
UY (1) | UY27793A1 (ko) |
WO (1) | WO2003095451A1 (ko) |
ZA (1) | ZA200408925B (ko) |
Families Citing this family (324)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
US20060122240A1 (en) * | 2002-11-05 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
KR20060065584A (ko) * | 2003-06-20 | 2006-06-14 | 아레나 파마슈티칼스, 인크. | N-페닐-피페라진 유도체 및 5ht2c 수용체 관련 질환의예방 또는 치료 방법 |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
US20080138444A1 (en) * | 2004-10-05 | 2008-06-12 | Bayer Healthcare Ag | Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction |
AU2005322183B2 (en) * | 2004-12-23 | 2012-03-29 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulator compositions and methods of use |
DE102005031575A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung |
DE102005031576A1 (de) * | 2005-07-06 | 2007-01-25 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden |
DE102005047945A1 (de) * | 2005-07-16 | 2007-01-18 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen |
DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
DE102006054757A1 (de) * | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
CA2686906A1 (en) * | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators, sgc activators and combinations for the treatment of urological disorders |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
DE102007035367A1 (de) * | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007042754A1 (de) * | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
CN102015591B (zh) * | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
JP2011519964A (ja) * | 2008-05-10 | 2011-07-14 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のsGC刺激剤、sGC活性化剤およびそれらの組合せ |
JP2011520997A (ja) * | 2008-05-29 | 2011-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 2−アルコキシ置換ジシアノピリジン類およびそれらの使用 |
DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008054205A1 (de) | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
AU2009322836B2 (en) * | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
CA2749730C (en) | 2009-01-17 | 2017-02-14 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
SI2504334T1 (sl) * | 2009-11-27 | 2014-11-28 | Bayer Intellectual Property Gmbh | Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata |
UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
UY33040A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
CA2784010A1 (en) | 2009-12-14 | 2011-06-23 | Bayer Intellectual Property Gmbh | Novel solvates of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
SG182819A1 (en) | 2010-02-05 | 2012-09-27 | Bayer Ip Gmbh | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
UA116521C2 (uk) * | 2010-05-26 | 2018-04-10 | Адверіо Фарма Гмбх | Застосування sgc-стимуляторів, sgc-активаторів окремо і в комбінації з інгібіторами фде5 для лікування системної склеродермії (ssc) |
MA34330B1 (fr) | 2010-05-27 | 2013-06-01 | Merck Sharp & Dohme | Activateurs de guanylate cyclase soluble |
WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
EP2585055A1 (de) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
JP6114189B2 (ja) | 2010-07-09 | 2017-04-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および/または予防のためのその使用 |
DE102011007891A1 (de) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | Annellierte 4-Aminopyrimidine und ihre Verwendung |
DE102011003315A1 (de) | 2011-01-28 | 2012-08-02 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimindine und Triazine und ihre Verwendung |
DE102010031148A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Ag | Annellierte 4-Aminopyrimidine und ihre Verwendung |
WO2012004259A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte 4 -aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
DE102010031149A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimidine und Triazine und ihre Verwendung |
KR101491938B1 (ko) | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ip 수용체 효능제 헤테로시클릭 화합물 |
DE102010031667A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung |
DE102010031665A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung |
DE102010031666A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Carbamat-substituierte Diaminopyrimidine und ihre Verwendung |
WO2012030957A2 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
ES2704455T3 (es) | 2010-09-01 | 2019-03-18 | Arena Pharm Inc | Formas farmacéuticas de liberación modificada de agonistas de 5-HT2C útiles para la gestión del peso |
WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
WO2012076466A2 (de) | 2010-12-07 | 2012-06-14 | Bayer Pharma Aktiengesellschaft | Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung |
DE102010062544A1 (de) | 2010-12-07 | 2012-06-14 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung |
DE102011006974A1 (de) | 2011-04-07 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung |
DE102012200356A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung |
US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
DE102011075399A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
DE102011007890A1 (de) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung |
DE102012200357A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung |
ES2583086T3 (es) | 2011-04-21 | 2016-09-19 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con fluoroalquilo y su uso |
DE102011075398A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridazine und ihre Verwendung |
EA201391769A1 (ru) | 2011-05-30 | 2014-04-30 | Астеллас Фарма Инк. | Имидазопиридиновые соединения |
KR20140054009A (ko) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
DE102012200354A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
DE102011078715A1 (de) | 2011-07-06 | 2013-01-10 | Bayer Pharma AG | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
MX2014000029A (es) | 2011-07-06 | 2014-02-17 | Bayer Ip Gmbh | Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de guanilato ciclasas solubles. |
WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
DE102011082041A1 (de) | 2011-09-02 | 2013-03-07 | Bayer Pharma AG | Substituierte annellierte Pyrimidine und ihre Verwendung |
DE102012200351A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte annellierte Pyrimidine und ihre Verwendung |
JP6054967B2 (ja) | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アネレート化ピリミジンおよびその使用 |
JP6189315B2 (ja) | 2011-11-25 | 2017-08-30 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換された5−フルオロ−1h−ピラゾロピリジン類を製造するための方法 |
CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
EP2802585A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
CN104053659B (zh) | 2012-01-13 | 2016-11-09 | 诺华股份有限公司 | 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类 |
JP6058698B2 (ja) | 2012-01-13 | 2017-01-11 | ノバルティス アーゲー | Ip受容体アゴニストの塩 |
EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2802583A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
ES2644781T3 (es) | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabiciclos sustituidos y su uso |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
WO2013157528A1 (ja) | 2012-04-16 | 2013-10-24 | トーアエイヨー株式会社 | 2環性化合物 |
UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
CA2879369C (en) | 2012-07-20 | 2020-09-22 | Bayer Pharma Aktiengesellschaft | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
EP2874993B1 (de) | 2012-07-20 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung |
KR20150070249A (ko) | 2012-10-09 | 2015-06-24 | 아레나 파마슈티칼스, 인크. | 체중 관리 방법 |
PL2927231T3 (pl) | 2012-11-30 | 2018-01-31 | Astellas Pharma Inc | Związki imidazopirydyny |
US9604981B2 (en) | 2013-02-13 | 2017-03-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2958914B1 (en) | 2013-02-21 | 2020-07-15 | Adverio Pharma GmbH | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
EP2961754B1 (de) | 2013-03-01 | 2016-11-16 | Bayer Pharma Aktiengesellschaft | Benzyl-substituierte pyrazolopyridine und ihre verwendung |
AP2015008637A0 (en) | 2013-03-01 | 2015-08-31 | Bayer Pharma AG | Trifluormethyl-substituted ring-fused pyrimidines and use thereof |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
ME03664B (me) | 2013-03-15 | 2020-10-20 | Cyclerion Therapeutics Inc | Sgc stimulator |
CA2914040A1 (en) * | 2013-06-03 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases |
JP2016522214A (ja) | 2013-06-04 | 2016-07-28 | バイエル・ファルマ・アクティエンゲゼルシャフト | 3−アリール−置換イミダゾ[1,2−a]ピリジンおよびその使用 |
PE20160201A1 (es) | 2013-07-10 | 2016-05-06 | Bayer Pharma AG | Bencil-1h-pirazol[3,4-b]piridinas y su uso |
US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
UY35693A (es) * | 2013-08-08 | 2015-02-27 | Bayer Pharma AG | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso |
WO2015036563A1 (de) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
CA2926223A1 (en) | 2013-10-07 | 2015-04-16 | Bayer Pharma Aktiengesellschaft | Cyclic thienouracil-carboxamides and use thereof |
RU2673245C2 (ru) | 2013-10-15 | 2018-11-23 | Тоа Эйо Лтд. | Производные 4-аминометилбензойной кислоты |
CN104327107A (zh) | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
WO2015063287A1 (en) | 2013-11-01 | 2015-05-07 | Bergen Teknologioverføring As | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome |
JP2016535769A (ja) | 2013-11-08 | 2016-11-17 | バイエル ファーマ アクチエンゲゼルシャフト | キマーゼ阻害薬としての置換されているウラシル類 |
EP3066098A1 (de) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
CN106304835A (zh) * | 2013-12-11 | 2017-01-04 | 铁木医药有限公司 | sGC刺激剂 |
WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
SG11201604949XA (en) | 2013-12-19 | 2016-07-28 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines |
US20160318866A1 (en) | 2013-12-19 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α2C拮抗薬としての置換されたビピペリジニル誘導体 |
JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
WO2015124544A1 (de) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
EP3126358A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
ES2761569T3 (es) | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
MY198066A (en) | 2014-08-01 | 2023-07-31 | Bayer Pharma AG | Method for the preparation of (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
CN107108658A (zh) | 2014-08-29 | 2017-08-29 | 拜耳医药股份有限公司 | 取代的环状嘧啶及其用途 |
WO2016030354A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Amino-substituierte annellierte pyrimidine und ihre verwendung |
US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
CN107406422B (zh) | 2014-09-17 | 2022-02-01 | 赛科理音医疗有限公司 | 作为sGC刺激剂的吡唑衍生物 |
MX2017003518A (es) | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
WO2016046157A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate |
CA2966256A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
CN104374861B (zh) * | 2014-11-10 | 2016-03-02 | 广东东阳光药业有限公司 | 一种用hplc分离测定利奥西呱原料药的有关物质的方法 |
CN104434845B (zh) * | 2014-11-12 | 2017-12-05 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
CN105777743A (zh) * | 2014-12-19 | 2016-07-20 | 奥浦顿(上海)医药科技有限公司 | 一种吡唑并[3,4-b]吡啶类化合物中间体的制备方法和应用 |
CN104530044B (zh) * | 2014-12-31 | 2016-07-13 | 安徽联创生物医药股份有限公司 | 一种利奥西呱的合成方法 |
WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
WO2016113415A1 (en) | 2015-01-16 | 2016-07-21 | Sandoz Ag | Process for the preparation of riociguat essentially free from genotoxic impurities |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
MX2017014057A (es) | 2015-05-06 | 2018-04-10 | Bayer Pharma AG | El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de ulceras digitales (du) concomitante con esclerosis sistemica (ssc). |
EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
ES2839248T5 (es) | 2015-07-23 | 2024-02-22 | Bayer Pharma AG | Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso |
WO2017025981A1 (en) * | 2015-08-13 | 2017-02-16 | Msn Laboratories Private Limited | Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof |
JOP20160186B1 (ar) | 2015-08-21 | 2021-08-17 | Bayer Pharma AG | طريقة لتحضير (4s)-4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا |
EP3373936A1 (en) | 2015-11-13 | 2018-09-19 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
JP2018536693A (ja) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 睡眠関連呼吸障害を治療するためのTASK−1およびTASK−2チャネルの遮断薬としての2−フェニル−3−(ピペラジノメチル)イミダゾ[1,2−a]ピリジン誘導体 |
JP2018538296A (ja) | 2015-12-10 | 2018-12-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ペルヒドロピロロ[3,4−c]ピロール誘導体およびその使用 |
EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
CN105461715B (zh) * | 2015-12-15 | 2017-03-29 | 郑州大明药物科技有限公司 | 一种利奥西呱中间体的合成方法 |
US10414766B2 (en) * | 2015-12-15 | 2019-09-17 | Alembic Pharmaceuticals Limited | Polymorph of Riociguat and its process for the preparation |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017121693A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte thiazol- und thiadiazolamide und ihre verwendung |
WO2017121692A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte sulfamide und ihre verwendung |
WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
US10526314B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
WO2017191107A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
US20190119251A1 (en) | 2016-05-03 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
WO2017191115A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
EP3458063A4 (en) | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHODS OF USING TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR FIBROTIC DISORDERS |
CN109563087A (zh) | 2016-07-07 | 2019-04-02 | 铁木医药有限公司 | sGC刺激剂的固体形式 |
CN109476686B (zh) | 2016-07-07 | 2022-01-18 | 赛克里翁治疗有限公司 | sGC刺激剂的磷前药 |
US10519154B2 (en) | 2016-07-11 | 2019-12-31 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
JOP20190005A1 (ar) * | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
PE20190607A1 (es) | 2016-09-02 | 2019-04-23 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
CA3037642A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N 3 -cyclically substituted thienouraciles and use thereof |
EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
CN107964011A (zh) * | 2016-10-19 | 2018-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代吡唑并吡啶类衍生物及其医药用途 |
EP3529244A1 (en) | 2016-10-20 | 2019-08-28 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
EP3538096B1 (en) | 2016-11-08 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
EP3538520A2 (en) * | 2016-11-08 | 2019-09-18 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
EA039175B1 (ru) * | 2016-12-14 | 2021-12-14 | Байер Акциенгезельшафт | Замещенные диазагетеробициклические соединения, способ их получения и их применение |
BR112019012251A2 (pt) | 2016-12-14 | 2019-11-05 | Respira Therapeutics Inc | métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
WO2018130226A1 (zh) * | 2017-01-16 | 2018-07-19 | 苏州科睿思制药有限公司 | 利奥西呱的新晶型及其制备方法和用途 |
BR112019016139A2 (pt) | 2017-02-08 | 2020-04-07 | Bristol-Myers Squibb Company | polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
BR112019021136A2 (pt) | 2017-04-10 | 2020-07-21 | Bayer Aktiengesellschaft | n-ariletil-2-arilquinolina-4-carboxamidas substituídas e uso das mesmas |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
CN108690016B (zh) * | 2017-04-11 | 2022-08-12 | 广东东阳光药业有限公司 | 吡唑并吡啶类化合物及其用途 |
WO2018188590A1 (en) | 2017-04-11 | 2018-10-18 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
CA3084421A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081353A1 (de) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituierte imidazopyridinamide und ihre verwendung |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EA202091025A1 (ru) | 2017-10-24 | 2020-07-30 | Байер Акциенгезельшафт | Пролекарства замещенных триазольных производных и их применения |
CA3084308A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081306A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
EP3700897A1 (en) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081299A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
US11337973B2 (en) | 2017-11-07 | 2022-05-24 | Bayer Aktiengesellschaft | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors |
CA3083986A1 (en) | 2017-12-01 | 2019-06-06 | Bayer Pharma Aktiengesellschaft | Method for producing (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient |
EP3727388A1 (en) | 2017-12-19 | 2020-10-28 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
MX2023004855A (es) | 2018-03-07 | 2023-11-24 | Cyclerion Therapeutics Inc | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
US20220324865A1 (en) | 2018-05-17 | 2022-10-13 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
CA3100271A1 (en) | 2018-05-22 | 2019-11-28 | Sunshine Lake Pharma Co., Ltd. | Phenyl-substituted dihydronaphthyridine compound and use thereof |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
BR112021000358A2 (pt) | 2018-07-11 | 2021-04-06 | Cyclerion Therapeutics, Inc. | Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais |
MX2021000904A (es) | 2018-07-24 | 2021-03-31 | Bayer Ag | Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada. |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN112469398A (zh) | 2018-07-24 | 2021-03-09 | 拜耳公司 | 可口服给药并具有缓释作用的药物剂型 |
CR20210277A (es) | 2018-11-27 | 2021-07-07 | Bayer Pharma AG | Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
MX2021005892A (es) | 2018-11-28 | 2021-06-23 | Topadur Pharma Ag | Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos. |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020165031A1 (de) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
CA3139209A1 (en) | 2019-05-07 | 2020-11-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
WO2020245342A1 (en) | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
GEP20247644B (en) | 2019-11-06 | 2024-07-10 | Bayer Ag | Inhibitors of adrenoreceptor adrac2 |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP4076398A4 (en) | 2019-12-16 | 2024-01-03 | Tenax Therapeutics, Inc. | LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF) |
US20230087609A1 (en) | 2020-02-21 | 2023-03-23 | Universiteit Maastricht | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME |
US20230083417A1 (en) | 2020-02-26 | 2023-03-16 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
WO2022057836A1 (zh) * | 2020-09-16 | 2022-03-24 | 南京明德新药研发有限公司 | 苯并脲环衍生物及其制备方法和应用 |
EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
US20240010684A1 (en) | 2020-11-04 | 2024-01-11 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
JP7458683B2 (ja) | 2020-12-10 | 2024-04-01 | バイエル・アクチエンゲゼルシヤフト | 眼科疾患の治療のためのsGC活性化剤の使用 |
CA3204595A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
US20240051935A1 (en) | 2020-12-10 | 2024-02-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
BR112023021851A2 (pt) | 2021-04-20 | 2024-02-06 | Tisento Therapeutics Inc | Estimulantes de sgc |
WO2022225902A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Treatment of cns diseases with sgc stimulators |
WO2022228365A1 (zh) * | 2021-04-27 | 2022-11-03 | 南京明德新药研发有限公司 | 六元杂芳并脲环的衍生物及其应用 |
WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
IL313920A (en) | 2021-12-29 | 2024-08-01 | Bayer Ag | Treatment of heart and lung disorders |
AR128147A1 (es) | 2021-12-29 | 2024-03-27 | Bayer Ag | Procedimiento para la preparación del ácido (5s)-[2-(4-carboxifenil)etil][2-(2-[3-cloro-4-(trifluorometil)bifenil-4-il]metoxifenil)etil]amino-5,6,7,8-tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo |
WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
WO2024086179A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
WO2024086182A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
CN117924280B (zh) * | 2024-03-20 | 2024-07-12 | 中国人民解放军军事科学院军事医学研究院 | 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
EP0934311B1 (de) | 1996-10-14 | 2009-05-13 | Bayer HealthCare AG | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
HU230154B1 (hu) | 1997-11-12 | 2015-09-28 | Bayer Intellectual Property Gmbh | Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
WO2002042299A1 (de) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Neue lactam-substituierte pyrazolopyridinderivate |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
DE10132416A1 (de) * | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
DE10350148B3 (de) | 2003-10-28 | 2005-02-10 | Daimlerchrysler Ag | Baureihe für einen Fahrzeugsitz |
-
2002
- 2002-05-08 DE DE10220570A patent/DE10220570A1/de not_active Withdrawn
-
2003
- 2003-04-25 WO PCT/EP2003/004304 patent/WO2003095451A1/de active IP Right Grant
- 2003-04-25 RU RU2004136277/04A patent/RU2339638C9/ru active
- 2003-04-25 NZ NZ536417A patent/NZ536417A/en not_active IP Right Cessation
- 2003-04-25 DE DE50303960T patent/DE50303960D1/de not_active Expired - Lifetime
- 2003-04-25 AT AT03727359T patent/ATE330957T1/de active
- 2003-04-25 MX MXPA04011003A patent/MXPA04011003A/es active IP Right Grant
- 2003-04-25 CA CA2485143A patent/CA2485143C/en not_active Expired - Lifetime
- 2003-04-25 DK DK03727359T patent/DK1506193T3/da active
- 2003-04-25 KR KR1020047017877A patent/KR101011864B1/ko active Protection Beyond IP Right Term
- 2003-04-25 US US10/513,869 patent/US7173037B2/en active Active
- 2003-04-25 AU AU2003233061A patent/AU2003233061B2/en active Active
- 2003-04-25 PL PL373336A patent/PL214985B1/pl unknown
- 2003-04-25 BR BRPI0309855A patent/BRPI0309855B8/pt not_active IP Right Cessation
- 2003-04-25 UA UA20041210078A patent/UA78314C2/uk unknown
- 2003-04-25 CN CNB038161605A patent/CN1330649C/zh not_active Expired - Lifetime
- 2003-04-25 SI SI200330432T patent/SI1506193T1/sl unknown
- 2003-04-25 PT PT03727359T patent/PT1506193E/pt unknown
- 2003-04-25 ES ES03727359T patent/ES2268363T3/es not_active Expired - Lifetime
- 2003-04-25 JP JP2004503467A patent/JP4455321B2/ja not_active Expired - Lifetime
- 2003-04-25 EP EP03727359A patent/EP1506193B1/de not_active Expired - Lifetime
- 2003-04-29 DO DO2003000639A patent/DOP2003000639A/es unknown
- 2003-05-05 GT GT200300101A patent/GT200300101A/es unknown
- 2003-05-06 UY UY27793A patent/UY27793A1/es not_active IP Right Cessation
- 2003-05-06 MY MYPI20031695A patent/MY136841A/en unknown
- 2003-05-06 AR ARP030101587A patent/AR039789A1/es active IP Right Grant
- 2003-05-07 PE PE2003000444A patent/PE20040197A1/es active IP Right Grant
- 2003-05-07 TW TW092112381A patent/TWI282792B/zh active
-
2004
- 2004-11-01 IL IL164958A patent/IL164958A/en active Protection Beyond IP Right Term
- 2004-11-04 ZA ZA2004/08925A patent/ZA200408925B/en unknown
- 2004-11-08 CU CU20040257A patent/CU23453B7/es unknown
- 2004-11-08 EC EC2004005414A patent/ECSP045414A/es unknown
- 2004-12-01 NO NO20045277A patent/NO329105B1/no not_active IP Right Cessation
- 2004-12-07 HR HRP20041166AA patent/HRP20041166B1/hr not_active IP Right Cessation
-
2006
- 2006-03-01 HK HK06102698A patent/HK1082247A1/xx not_active IP Right Cessation
- 2006-09-14 CY CY20061101309T patent/CY1105579T1/el unknown
-
2014
- 2014-04-01 NL NL300659C patent/NL300659I2/nl unknown
- 2014-04-02 LU LU92419C patent/LU92419I2/fr unknown
- 2014-04-11 FR FR14C0032C patent/FR14C0032I2/fr active Active
- 2014-04-25 CY CY2014018C patent/CY2014018I2/el unknown
- 2014-05-12 BE BE2014C030C patent/BE2014C030I2/fr unknown
- 2014-07-18 NO NO2014018C patent/NO2014018I2/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101011864B1 (ko) | 카르바메이트-치환된 피라졸로피리딘 | |
JP4589720B2 (ja) | 2−(1−ベンジル−1h−ピラゾロ(3,4−b)ピリジン−3−イル)−5−(4−ピリジニル)−4−ピリミジンアミン誘導体およびグアニル酸シクラーゼ刺激因子としてのそれらの使用 | |
US6693102B2 (en) | Pyridine-substituted pyrazolopyridine derivatives | |
US20040067937A1 (en) | Novel sulfonamide-substituted pyrazolopyridine derivatives | |
KR20030065519A (ko) | 신규 피리딘 치환 피라졸로피리딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 4 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180103 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 10 |